HeartBeam (NASDAQ: BEAT) has announced the launch of a pilot study to evaluate its proprietary on-demand 12-lead ECG patch for detecting coronary artery disease and ischemia—a condition characterized by inadequate blood flow and oxygen supply to tissue. The study marks a significant step in the development of the HeartBeam patch, which aims to address a critical gap in ambulatory cardiac monitoring.
Coronary artery disease remains a leading cause of death globally, often progressing silently until a major cardiac event occurs. Current patch-based ambulatory monitors are unable to detect ischemia, limiting their clinical utility for high-risk patients. HeartBeam's patch is designed to change that by generating clinical-grade 12-lead ECGs on demand, potentially providing earlier detection and intervention.
“Ischemia detection has not been possible on patch-based ambulatory monitors, and they do not provide clinical-grade insights over an extended period of time,” said HeartBeam CEO Robert Eno. “The HeartBeam patch is designed to change that. A device capable of generating an on-demand 12-lead ECG could disrupt the $2 billion long-term continuous monitor and mobile cardiac telemetry (MCT) markets.”
For more details on the study and HeartBeam's technology, visit the company's newsroom at https://ibn.fm/BEAT. The full terms of use and disclaimers are available at http://IBN.fm/Disclaimer.
This announcement underscores the growing importance of innovative cardiac monitoring solutions in combating heart disease. If successful, HeartBeam's patch could offer a non-invasive, accessible tool for identifying patients at risk of ischemia, potentially reducing the burden of cardiovascular events and improving outcomes.
